Patents by Inventor Nicholas K. Tonks
Nicholas K. Tonks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10973835Abstract: A method is disclosed for altering the redox equilibrium of a transmembrane receptor-like protein tyrosine phosphatase (RPTP), particularly a type IIa RPTP, by chemically modulating the activity through contact of such an enzyme with a diaryl boron compound that preferentially reacts with an RPTP in an oxidized state (CyS-OH). This redox modulation is most readily observed and put to use by assaying the inhibition of the phosphatase activity of the RPTP. Such an assay can be carried out on an enzyme in vitro or by contacting the enzyme in a living organism (in vivo). A useful diaryl boron compound corresponds in structure to Formula I in which Ar-1, Ar-2, R1, R2, R3 and R4 are defined within. A pharmaceutical composition containing a useful diaryl boron compound is also disclosed, as are particularly preferred diaryl boron compounds.Type: GrantFiled: March 2, 2018Date of Patent: April 13, 2021Assignees: The Penn State Research Foundation, Cold Spring Harbor LaboratoryInventors: Stephen J. Benkovic, Nicholas K. Tonks, Chun Yu Liu, Navasona Krishnan, Chunliang Liu
-
Publication number: 20210052614Abstract: A method is disclosed for altering the redox equilibrium of a transmembrane receptor-like protein tyrosine phosphatase (RPTP), particularly a type IIa RPTP, by chemically modulating the activity through contact of such an enzyme with a diaryl boron compound that preferentially reacts with an RPTP in an oxidized state (CyS-OH). This redox modulation is most readily observed and put to use by assaying the inhibition of the phosphatase activity of the RPTP. Such an assay can be carried out on an enzyme in vitro or by contacting the enzyme in a living organism (in vivo). A useful diaryl boron compound corresponds in structure to Formula I in which Ar-1, Ar-2, R1, R2, R3 and R4 are defined within. A pharmaceutical composition containing a useful diaryl boron compound is also disclosed, as are particularly preferred diaryl boron compounds.Type: ApplicationFiled: November 3, 2020Publication date: February 25, 2021Inventors: Stephen J. Benkovic, Nicholas K. Tonks, Chun Yu Liu, Navasona Krishnan, Chunliang Liu
-
Publication number: 20180258106Abstract: A method is disclosed for altering the redox equilibrium of a transmembrane receptor-like protein tyrosine phosphatase (RPTP), particularly a type IIa RPTP, by chemically modulating the activity through contact of such an enzyme with a diaryl boron compound that preferentially reacts with an RPTP in an oxidized state (CyS-OH). This redox modulation is most readily observed and put to use by assaying the inhibition of the phosphatase activity of the RPTP. Such an assay can be carried out on an enzyme in vitro or by contacting the enzyme in a living organism (in vivo). A useful diaryl boron compound corresponds in structure to Formula I in which Ar-1, Ar-2, R1, R2, R3 and R4 are defined within. A pharmaceutical composition containing a useful diaryl boron compound is also disclosed, as are particularly preferred diaryl boron compounds.Type: ApplicationFiled: March 2, 2018Publication date: September 13, 2018Inventors: Stephen J. Benkovic, Nicholas K. Tonks, Chun Yu Liu, Navasona Krishnan, Chunliang Liu
-
Publication number: 20160113989Abstract: A method for formulating A250, a biologically active substance and fraction of wheat germ ferment/fermented wheat germ extract (FWGE), including formulation A250, the processes for their production, the pharmaceutical preparations containing them, and their uses.Type: ApplicationFiled: October 22, 2014Publication date: April 28, 2016Inventors: Mate Hidvegi, Gyula Bencze, Gyorgy Keri, Laszlo Orfi, Darryl Pappin, Nicholas K. Tonks, James Watson
-
Publication number: 20120164132Abstract: Biologically active substances and fractions of wheat germ ferment/fermented wheat germ extract (FWGE), including formulation A250, the processes for their production, the pharmaceutical preparations containing them, and their uses.Type: ApplicationFiled: July 11, 2011Publication date: June 28, 2012Inventors: Mate Hidvegi, Gyula Bencze, Gyorgy Keri, Laszlo Orfi, Darryl Pappin, Nicholas K. Tonks, James Watson
-
Patent number: 7205121Abstract: Proteins are identified from human breast tumor cell lines (MDA-MB-231, T-47D and T-47D/Met) that interact specifically with the substrate-trapping mutant form of Density Enhanced Phosphatase-1 (DEP-1). These proteins include the functional component p120 catenin (p120ctn), the adaptor protein Gab 1, and the HGF/SF receptor Met. The invention relates to isolated complexes comprising DEP-1 polypeptides in specific association with Met, Gab 1, or p120ctn, identified herein as DEP-1 substrate polypeptides. Screening assays for agents that alter DEP-1 interaction with DEP-1 substrate polypeptides are also disclosed, as are methods for altering biological signals in cells that are transduced via DEP-1 pathways.Type: GrantFiled: November 26, 2003Date of Patent: April 17, 2007Assignee: Cold Spring Harbor LaboratoryInventors: Helena L. Palka-Hamblin, Nicholas K. Tonks
-
Patent number: 7195762Abstract: Novel Type III density enhanced protein tyrosine phosphatases are disclosed and exemplified by human DEP-1 enzyme. Polynucleotides encoding huDEP-1 are disclosed, along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for DEP-1 are also disclosed as useful for modulating the biological activities of DEP-1.Type: GrantFiled: March 13, 2003Date of Patent: March 27, 2007Assignee: Cold Spring Harbor LaboratoryInventors: Nicholas K Tonks, Arne Ostman
-
Publication number: 20040161821Abstract: Proteins are identified from human breast tumor cell lines (MDA-MB-231, T-47D and T-47D/Met) that interact specifically with the substrate-trapping mutant form of Density Enhanced Phosphatase-1 (DEP-1). These proteins include the functional component p120 catenin (p120ctn), the adaptor protein Gab 1, and the HGF/SF receptor Met. The invention relates to isolated complexes comprising DEP-1 polypeptides in specific association with Met, Gab 1, or p120ctn, identified herein as DEP-1 substrate polypeptides. Screening assays for agents that alter DEP-1 interaction with DEP-1 substrate polypeptides are also disclosed, as are methods for altering biological signals in cells that are transduced via DEP-1 pathways.Type: ApplicationFiled: November 26, 2003Publication date: August 19, 2004Applicant: Cold Spring Harbor LaboratoryInventors: Helena L. Palka-Hamblin, Nicholas K. Tonks
-
Publication number: 20040121353Abstract: Compositions and methods relating to small interfering RNA (siRNA) polynucleotides are provided as pertains to modulation of biological signal transduction. Shown are siRNA polynucleotides that interfere with expression of TCPTP, a member of the protein tyrosine phosphatase (PTP) class of enzymes that mediate signal transduction. In certain preferred embodiments siRNA modulate signal transduction pathways comprising human or murine TCPTP and, in certain further embodiments, insulin receptor, c-jun kinase (JNK) and/or Jak2. Modulation of TCPTP-mediated biological signal transduction has uses in diseases associated with defects in cell proliferation, cell differentiation and/or cell survival, such as metabolic disorders (including diabetes and obesity), cancer, autoimmune disease, infectious and inflammatory disorders and other conditions.Type: ApplicationFiled: May 23, 2003Publication date: June 24, 2004Applicants: CEPTYR, Inc., Cold Spring Harbor Laboratory, Inc.Inventors: Stephen Patrick Lewis, Nicholas K. Tonks, Tzu-Ching Meng, Richard Klinghoffer
-
Publication number: 20030223975Abstract: Compositions and methods relating to PTP1B associated disorders are provided, based on the discovery that a Y-box protein binding site is present as a transcription enhancer sequence in the promoter region situated upstream (i.e., 5′ to) of the human PTP1B gene. This site, situated at nucleotides −155 through −132 of the human PTP1B gene, mediates specific binding interactions with the YB-1 transcription regulatory factor, a member of the Y-box family of proteins. YB-1-targeted antisense constructs reduced PTP1B expression levels, providing an alternative to PTP1B active-site directed regulation of PTP1B activity.Type: ApplicationFiled: March 11, 2003Publication date: December 4, 2003Applicant: Cold Spring Harbor LaboratoryInventors: Nicholas K. Tonks, Toshiyuki Fukada
-
Publication number: 20030215899Abstract: The invention relates to a method of identifying any protein tyrosine phosphatase (PTP) that undergoes reversible modification of PTP active site invariant cysteine within a cell, such that the phosphatase is transiently protected from irreversible active site invariant cysteine-directed PTP inactivating agents. Methods related to regulation of PTPs by reactive oxygen species (ROS) in a cellular environment are provided. Multiple PTPs are shown to be reversibly oxidized and inactivated following treatment of cells with H2O2 or with physiological stimuli that promote ROS formation, and inhibition of PTP function is shown to contribute to ROS-induced mitogenesis. Transient oxidation of the PTP catalytic site invariant cysteine is exploited in methods to identify which of multiple candidate PTPs are components of a given biological signal transduction pathway, without a requirement for first specifically purifying any particular candidate PTP.Type: ApplicationFiled: February 12, 2003Publication date: November 20, 2003Applicants: CEPTYR, Inc., Cold Spring Harbor LaboratoryInventors: Tzu-Ching Meng, Nicholas K. Tonks, Deborah E. Cool
-
Publication number: 20030148491Abstract: Novel Type III density enhanced protein tyrosine phosphatases are disclosed and exemplified by human DEP-1 enzyme. Polynucleotides encoding huDEP-1 are disclosed, along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for DEP-1 are also disclosed as useful for modulating the biological activities of DEP-1.Type: ApplicationFiled: March 13, 2003Publication date: August 7, 2003Applicant: COLD SPRING HARBOR RESEARCH LABORATORYInventors: Nicholas K. Tonks, Arne Ostman
-
Publication number: 20030113294Abstract: DNA which encodes a protein homologous to the protein tyrosine phosphatases (PTPases) which catalyze the dephosphorylation of proteins in which tyrosyl residues have been phosphorylated through the action of a protein kinase. The protein, which appears as if it will localize to focal adhesions, is also the subject of the present invention. In particular, it relates to CDNA encoding a protein, referred to as PTPH1.Type: ApplicationFiled: November 12, 2002Publication date: June 19, 2003Applicant: Cold Spring Harbor LaboratoryInventor: Nicholas K. Tonks
-
Patent number: 6552169Abstract: Novel Type III density enhanced protein tyrosine phosphatases are disclosed and exemplified by human DEP-1 enzyme. Polynucleotides encoding huDEP-1 are disclosed, along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for DEP-1 are also disclosed as useful for modulating the biological activities of DEP-1.Type: GrantFiled: November 23, 1999Date of Patent: April 22, 2003Assignee: Cold Spring Harbor LaboratoryInventors: Nicholas K. Tonks, Arne Ostman
-
Patent number: 6479640Abstract: An antibody is provided that is specific for a PTPH1 protein, a phosphatase that dephosphorylates phosphotyrosine residues in phosphoproteins having tyrosyl residues that are phosphorylated by tyrosine kinases. The PTPH1 protein localizes to focal adhesions, a major site of action for oncogenic protein tyrosine kinases. PTPH1 overexpression may counter the effects of oncogenic protein tyrosine kinases, such as those of transforming viruses, by interfering with or reversing cell transformation that is associated with the activity of a protein tyrosine kinase.Type: GrantFiled: May 3, 2001Date of Patent: November 12, 2002Assignee: Cold Spring Harbor LaboratoryInventor: Nicholas K. Tonks
-
Publication number: 20020049179Abstract: DNA which encodes a protein homologous to the protein tyrosine phosphatases (PTPases) which catalyze the dephosphorylation of proteins in which tyrosyl residues have been phosphorylated through the action of a protein kinase. The protein, which appears as if it will localize to focal adhesions, is also the subject of the present invention. In particular, it relates to cDNA encoding a protein, referred to as PTPH1.Type: ApplicationFiled: May 3, 2001Publication date: April 25, 2002Applicant: Cold Spring Harbor LaboratoryInventor: Nicholas K. Tonks
-
Patent number: 6114140Abstract: Novel Type III density enhanced protein tyrosine phosphatases are disclosed and exemplified by human DEP-1 enzyme. Polynucleotides encoding huDEP-1 are disclosed, along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for DEP-1 are also disclosed as useful for modulating the biological activities of DEP-1.Type: GrantFiled: May 12, 1997Date of Patent: September 5, 2000Assignee: Cold Spring Harbor LaboratoryInventors: Nicholas K. Tonks, Arne Ostman
-
Patent number: 5863781Abstract: DNA which encodes a protein homologous to the protein tyrosine phosphatases (PTPases) which catalyze the dephosphorylation of proteins in which tyrosyl residues have been phosphorylated through the action of a protein kinase. The protein, which appears as if it will localize to focal adhesions, is also the subject of the present invention. In particular, it relates to cDNA encoding a protein, referred to as PTPH1.Overexpression of PTPH1 may be a powerful approach to countering the effects of oncogenic protein tyrosine kinases, such as those of transforming viruses, and interfering with or reversing cell transformation. This would provide a means of preventing or reversing abnormally high levels of phosphotyrosine associated with any disease or condition, such as preventing or reversing malignancy associated with the activity of a protein tyrosine kinase.Type: GrantFiled: December 4, 1996Date of Patent: January 26, 1999Assignee: Cold Spring Harbor LaboratoryInventor: Nicholas K. Tonks
-
Patent number: 5595911Abstract: DNA which encodes a protein homologous to the protein tyrosine phosphatases (PTPases) which catalyze the dephosphorylation of proteins in which tyrosyl residues have been phosphorylated through the action of a protein kinase. The protein, which appears as if it will localize to focal adhesions, is also the subject of the present invention. In particular, it relates to cDNA encoding a protein, referred to as PTPH1.Type: GrantFiled: August 16, 1993Date of Patent: January 21, 1997Assignee: Cold Spring Harbor LaboratoryInventor: Nicholas K. Tonks